MSLN and pancreatic adenocarcinoma: In the current study, we assess the safety, immunogenicity, and protective efficacy of a therapeutic MVA virus vaccine expressing mesothelin (MVAmeso) in a heterotopic pancreatic tumor model using the pancreatic adenocarcinoma cell line Panc02 that expresses mesothelin in culture and in tumors in the mouse model [7].